Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preeti Manandhar

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Pharmacology Research & Perspectives|January 27, 2022
Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodonePreeti Manandhar, Mark Connor, Marina Santiago
Methods in Molecular Biology (Clifton, N.J.)|September 25, 2020
Evaluating Opioid-Mediated Adenylyl Cyclase Inhibition in Live Cells Using a BRET-Based AssayPreeti Manandhar, Shivani Sachdev, Marina Santiago
Peerj|May 6, 2021
Do gabapentin or pregabalin directly modulate the µ receptor?Preeti Manandhar, Bridin Patricia Murnion, Natasha L Grimsey, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Pharmacology Research & Perspectives|January 27, 2022
Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodonePreeti Manandhar, Mark Connor, Marina Santiago
Methods in Molecular Biology (Clifton, N.J.)|September 25, 2020
Evaluating Opioid-Mediated Adenylyl Cyclase Inhibition in Live Cells Using a BRET-Based AssayPreeti Manandhar, Shivani Sachdev, Marina Santiago
Peerj|May 6, 2021
Do gabapentin or pregabalin directly modulate the µ receptor?Preeti Manandhar, Bridin Patricia Murnion, Natasha L Grimsey, et al.
Science Signaling|April 3, 2020
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonistsAlexander Gillis, Arisbel B Gondin, Andrea Kliewer, et al.
Pageof 1